Role of interleukin 16 in multiple myeloma pathogenesis: A potential novel therapeutic target?

Journal of the National Cancer Institute

Volumn 104, Issue 13, 2012, Pages 964-965

  Mahindra, Anuj ^a,c   Anderson, Kenneth C ^b,c  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CD34 ANTIGEN; INTERLEUKIN 16; INTERLEUKIN 2 RECEPTOR ALPHA; LENALIDOMIDE; MESSENGER RNA; SMALL INTERFERING RNA; SYNDECAN 1;

ANTIGEN EXPRESSION; APOPTOSIS; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CARCINOGENESIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; EDITORIAL; GENE SILENCING; HUMAN; IMMUNOHISTOCHEMISTRY; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION;

BONE MARROW CELLS; FEMALE; HUMANS; INTERLEUKIN-6; MALE; MULTIPLE MYELOMA; PLASMA CELLS;

EID: 84863974117     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djs274     Document Type: Editorial

References (22)

1. Cruikshank W, Kornfeld H, Berman J, Chupp G, Keane J, Center D. Biological activity of interleukin-16. Nature. 1996;382(6591):501-502.
2. Cruikshank WW, Kornfeld H, Center DM. Interleukin-16. J Leukoc Biol. 2000;67(6):757-766.
3. Atanackovic D, Hilebrandt Y, Templin J, et al. Role of interleukin-16 in multiple myeloma. J Natl Cancer Inst. 2012;104(13). doi:10.1093/jnci/djs257.
4. Center DM, Kornfeld H, Cruikshank WW. Interleukin 16 and its function as a CD4 ligand. Immunol Today. 1996;17(10):476-481.
5. Theodore AC, Center DM, Nicoll J, Fine G, Kornfeld H, Cruikshank WW. CD4 ligand IL-16 inhibits the mixed lymphocyte reaction. J Immunol. 1996;157(5):1958-1964.
6. Cruikshank WW, Lim K, Theodore AC, et al. IL-16 inhibition of CD3-dependent lymphocyte activation and proliferation. J Immunol. 1996;157(12):5240-5248.
7. Newell MK, Haughn LJ, Maroun CR, Julius MH. Death of mature T cells by separate ligation of CD4 and the T-cell receptor for antigen. Nature. 1990;347(6290):286-289.
8. Sekigawa I, Koshino K, Hishikawa T, et al. Inhibitory effect of the immunosuppressant FK506 on apoptotic cell death induced by HIV-1 gp120. J Clin Immunol. 1995;15(6):312-317.
9. Lee S, Kaneko H, Sekigawa I, Tokano Y, Takasaki Y, Hashimoto H. Circulating interleukin-16 in systemic lupus erythematosus. Br J Rheumatol. 1998;37(12):1334-1337.
10. Maeda N, Sekigawa I, Iida N, Matsumoto M, Hashimoto H, Hirose S. Relationship between CD4 +CD8+ T cell ratio and T cell activation in systemic lupus erythematosus. Scand J Rheumatol. 1999;28(3):166-170.
11. Richmond J, Tuzova M, Parks A, et al. Interleukin-16 as a marker of Sezary syndrome onset and stage. J Clin Immunol. 2011;31(1):39-50.
12. Yellapa A, Bahr JM, Bitterman P, et al. Association of interleukin 16 with the development of ovarian tumor and tumor-associated neoangiogenesis in laying hen model of spontaneous ovarian cancer. Int J Gynecol Cancer. 2012;22(2):199-207.
13. Comperat E, Roupret M, Drouin SJ, et al. Tissue expression of IL16 in prostate cancer and its association with recurrence after radical prostatectomy. Prostate. 2010;70(15):1622-1627.
14. Gao LB, Liang WB, Xue H, et al. Genetic polymorphism of interleukin-16 and risk of nasopharyngeal carcinoma. Clin Chim Acta. 2009;409(1-2):132-135.
15. Gao LB, Rao L, Wang YY, et al. The association of interleukin-16 polymorphisms with IL-16 serum levels and risk of colorectal and gastric cancer. Carcinogenesis. 2009;30(2):295-299.
16. Alexandrakis MG, Passam FH, Kyriakou DS, et al. Serum level of interleukin-16 in multiple myeloma patients and its relationship to disease activity. Am J Hematol. 2004;75(2):101-106.
17. Mathy NL, Scheuer W, Lanzendorfer M, et al. Interleukin-16 stimulates the expression and production of pro-inflammatory cytokines by human monocytes. Immunology. 2000;100(1):63-69.
18. Rofani C, Luchetti L, Testa G, et al. IL-16 can synergize with early acting cytokines to expand ex vivo CD34+ isolated from cord blood. Stem Cells Dev. 2009;18(4):671-682.
19. Bataille R, Barlogie B, Lu ZY, et al. Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. Blood. 1995;86(2):685-691.
20. Fulciniti M, Hideshima T, Vermot-Desroches C, et al. A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma. Clin Cancer Res. 2009;15(23):7144-7152.
21. Hideshima T, Anderson KC. Novel therapies in MM: from the aspect of preclinical studies. Int J Hematol. 2011;94(4):344-354.
22. Mahindra A, Laubach J, Raje N, Munshi N, Richardson PG, Anderson K. Latest advances and current challenges in the treatment of multiple myeloma. Nat Rev Clin Oncol. 2012;9(3):135-143.